Mount Sinai Health System faculty will be presenting research updates on a lymphoma vaccine clinical trial, the best dosing for a drug against metastatic cancer, and new treatment strategies in relapsed multiple myeloma at the American Society of Clinical Oncology (ASCO) annual meeting, May 29 – June 2, 2015, in Chicago.
CHICAGO — Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase 3 clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent.
A new phase 3 study in some of the most difficult-to-treat patients, women with endocrine-resistant disease, showed that the newly approved drug, palbociclib, more than doubled the time to cancer recurrence for women with hormone-receptor (HR+) positive metastatic breast cancer.
The public is invited to a free talk by doctors and patients on neuromodulation before a three-day world congress brings more than 1,300 international experts to Montreal to discuss this promising therapeutic approach.
Investigators at Fred Hutchinson Cancer Research Center will share new research findings at the annual meeting of the American Society of Clinical Oncology, or ASCO, which is being held May 29–June 2 in Chicago.
A team of researchers led by Ludwig Cancer Research investigator Luis Diaz has identified a genetic malfunction that predicts the effectiveness of response to a groundbreaking immunotherapy. The results of their Phase 2 clinical trial reveal that, regardless of its tissue of origin, tumors whose cells are deficient in repairing mismatched DNA sequences—and so preventing mutations—are far more susceptible to the checkpoint inhibitor pembrolizumab than those that retain this ability. Their findings were announced today at the American Society for Clinical Oncology Annual Meeting and will be published online May 30 in the New England Journal of Medicine (NEJM).
A multiplatform biomarker analysis of squamous cell anal carcinoma samples led by Roswell Park in conjunction with Caris Life Sciences has revealed several actionable targets.
Promising clinical trial results presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast cancer, in one case specifically against brain metastases and in another case in overall survival of heavily pretreated HER2+ breast cancer patients.
A University of Colorado Cancer Center study presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 shows decreased sexual activity in women following treatment for gynecologic cancers, down from 6.1-6.8 times per month before treatment to 2.6-4.9 times per month after treatment.
Cerebral palsy is the most common cause of childhood disability in the world, but is understudied, especially in developing countries. An ongoing international partnership in Botswana has done the first rigorous study of CP outcomes in Africa.
A collaborative team of researchers led by Alex A. Adjei, MD, PhD, FACP, of Roswell Park Cancer Institute (RPCI) will share results from the first clinical study of the anticancer effects of the novel agent entolimod at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting in Chicago. Their findings confirm preclinical evidence that the agent, which is derived from salmonella flagellin, is worthy of further investigation as treatment for some of the most common and most resilient solid-tumor cancers.
The incidence of melanoma, a deadly form of skin cancer, has increased by more than 250% among children, adolescents and young adults since 1973, according to award-winning research to be presented by Roswell Park Cancer Institute (RPCI) at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting in Chicago.
Roswell Park Cancer Institute (RPCI) researchers have developed an accurate, individualized post-operative survival calculator and integrated the technology into a mobile application compatible with smartphone technology for oncologists and patients diagnosed with colon cancer. Information about the calculator will be presented at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting in Chicago.
Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer. Scott J. Antonia, M.D., Ph.D., chair of the Thoracic Oncology Department at Moffitt Cancer Center will be presenting data from a phase 1b dose-escalation and expansion study of MEDI4736 combined with tremelimumab at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago.
Prostate cancer is the second most common type of cancer in men and is predicted to result in an estimated 220,00 cases in the United States in 2015. In recent years, an emphasis has been placed on chemoprevention – the use of agents to prevent the development or progression of prostate cancer. A team of researchers led by Nagi B. Kumar, Ph.D., R.D., F.A.D.A. at Moffitt Cancer Center recently published results of a randomized trial that assessed the safety and effectiveness of the active components in green tea to prevent prostate cancer development in men who have premalignant lesions. The results will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Chronic myelomonocytic leukemia (CMML) is a rare type of myelodysplastic, myeloproliferative neoplasm characterized by increased numbers of peripheral monocytes and less than 20 percent blasts. CMML has few treatment options and patients only survive on average for 12 to 24 months. Preclinical studies suggest that JAK2 inhibitors may be an effective treatment option for CMML. Eric Padron, M.D., assistant member of the Malignant Hematology Program at Moffitt Cancer Center will report on the first phase 1 study of the JAK2 inhibitor ruxolitinib in CMML patients at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago.
The monoclonal antibody nivolumab has shown promise as a therapeutic agent, particularly by improving the survival rates of melanoma patients. Jeffrey S. Weber, M.D., Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center at Moffitt Cancer Center will be presenting data from a retrospective analysis of the safety of nivolumab in 4 ongoing phase I-III studies in melanoma patients at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago
Phase I/II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK+ non-small cell lung cancer (NSCLC), with 58 of 78 ALK+ patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor. Progression-free survival (PFS) in patients previously treated with crizotinib was 13.4 months.
Obesity is a risk factor for breast cancer. A multi-institutional study presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 shows that female breast cancer survivors are able to lose weight through modest lifestyle changes.
Researchers from the Abramson Cancer Center of the University of Pennsylvania and Penn’s Perelman School of Medicine will present results from several clinical trials and other key studies during the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 through June 2.
David Mulvihill, MD, chief resident of radiation oncology at Rutgers Cancer Institute of New Jersey, has been selected to receive a Young Investigator Award from the Conquer Cancer Foundation of the American Society of Clinical Oncology. Dr. Mulvihill will receive $50,000 to support his study entitled “Childhood Radiation Exposure from Interventional Cardiology Procedures and Subsequent Cancer Risk.”
NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center will have a high profile at the 51st Annual Meeting of the American Society for Clinical Oncology (ASCO), with researchers presenting close to 30 abstracts accepted for oral, poster and publication presentations.
Ludwig Cancer Research previewed today the new findings that will be presented by Ludwig scientists at this year’s American Society for Clinical Oncology Annual Meeting in Chicago, Ill., May 29 – June 2. Ludwig researchers will present recent data from early and late stage clinical trials and participate in a number of plenary and educational sessions.
Experts from the Mayo Clinic, Cleveland Clinic, Stanford, PENN, UNC, and the NIH will offer education and networking opportunities for people, families, and friends living with vasculitis, a family of rare autoimmune diseases.
Certain proteins may slow the devastating memory loss caused by Alzheimer’s disease, according to a groundbreaking Iowa State University study.
Chronic obstructive pulmonary disease, or COPD, is associated with increased risk of dying from a cardiovascular disease such as heart failure or a heart attack, as well as diseases not associated with the heart. However, COPD is not by itself associated with increased likelihood of having a stroke or a systemic embolism, according to a new research study.
Data from the ILUMIEN II trial found that guidance from optimal coherence tomography (OCT) was associated with comparable stent expansion as guidance from intravascular ultrasound (IVUS) in patients undergoing percutaneous coronary intervention (PCI). Results from the study were presented today at EuroPCR 2015, the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions.
ATS 2015, DENVER ─ Treatment of COPD with inhaled corticosteroids (ICS) may decrease the risk of dying from pneumonia and from other causes despite being associated with an increase in the occurrence of pneumonia, according to a new meta-analysis presented at the 2015 American Thoracic Society International Conference.
Issues surrounding cost effectiveness and related clinical questions were taken up in the Second Plenary Session at the ISPOR 20th Annual International Meeting, entitled, “Cost-Effectiveness and Clinical Practice Guidelines: Have We Reached a Tipping Point?”
Patient-selected music during weaning from prolonged mechanical ventilation could benefit patients by decreasing their heart rate and anxiety, according to a study presented at the 2015 American Thoracic Society International Conference.
Critically ill patients who have been mechanically ventilated for more than seven days are at greatly increased risk for functional impairment and mortality at one year following discharge from the intensive care unit (ICU), according to a new study presented at the 2015 American Thoracic Society International Conference.
Living in a rural area and being poor are risk factors for chronic obstructive pulmonary disease (COPD), said Sarath Raju, MD, MPH, Johns Hopkins School of Medicine, Baltimore, Maryland, lead author of a study presented at the 2015 American Thoracic Society International Conference.
A new study has shown that many lung cancer survivors are at high risk for developing another lung cancer or having their cancer return after completing treatment. Conducted by researchers in the U.S., the study specifically looked at lung cancer survivors from three different institutions who had shown no further evidence of having the disease after completing the required treatment for lung cancer.
Researchers at the University of Colorado suggest that the portion of the brain devoted to hearing can become reorganized even with early-stage hearing loss, and may play a role in cognitive decline. They have applied fundamental principles of neuroplasticity, the ability of the brain to forge new connections, to determine the ways it adapts to hearing loss, as well as the consequences of those changes, and their findings will be presented at ASA’s 169th meeting.
\Severe sepsis is a significant cause of rehospitalization along the lines of nationally recognized outcome measures and more commonly discussed conditions such as heart failure (HF) and pneumonia, said Darya Rudym, MD, New York University School of Medicine, New York, lead author of a study presented at the 2015 American Thoracic Society International Conference.
Asthma is one of the most common chronic diseases in children, and it can only be managed, not cured. It affects a disproportionally higher percentage of low-income, urban minority children, and is also the most common disease-related reason for children missing school. This can have a negative effect on their academic achievement, as well as later success in life.
Speakers at the 20th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), held May 18th to 20th in Philadelphia, discussed the status of the Learning Health Care System in their first plenary session, entitled “Taking Stock of the Learning Health Care System: What Have We Achieved and Why Does it Matter?”
Severe obstructive sleep apnea (OSA) and excessive daytime sleepiness are associated with an increased risk of depression in men, according to a new community-based study of Australian men, which was presented at the 2015 American Thoracic Society International Conference.
Patients undergoing percutaneous coronary intervention (PCI), a coronary artery widening procedureused to treat heart disease, are at high risk for obstructive sleep apnea (OSA), according to new research presented at the 2015 American Thoracic Society International Conference.
ATS 2015, DENVER—Pulmonary rehabilitation (PR) treatment could be a valuable addition to comprehensive therapy in patients with obstructive sleep apnea (OSA) syndrome, according to a new study. The study was presented at the 2015 American Thoracic Society International Conference.
Researchers have found that adding genetic information to a former or current smoker’s clinical risk profile results in a reclassification of their risk for lung cancer in about one in four patients. Preliminary findings from their lung cancer screening feasibility study also suggests that those whose genetic and clinical risk placed them in the highest risk category were more likely to adhere to follow-up computed tomography (CT) scans during screening.
Studies have shown that both air pollution and impaired lung function can cause cognitive deficits, but it was unclear whether air pollution diminishes cognition by reducing breathing ability first or whether air pollution represents an independent risk factor for cognitive deficit. Now a new study conducted by German and Swiss researchers has answered that question: air pollution directly affects cognition and is not mediated by lung function.
Gastroesophageal reflux disease (GERD), being female, and certain scores on the St. George’s Respiratory Questionnaire (SGRQ) were associated with exacerbations of chronic obstructive pulmonary disease (COPD) in subjects using long-acting controller medication, according to a study presented at the 2015 American Thoracic Society International Conference.
New proof-of-concept research suggests the potential for engineering replacement intestine tissue in the lab, a treatment that could be applied to infants born with a short bowel and adults having large pieces of gut removed due to cancer or inflammatory bowel disease.
Trending news releases with the most views in a single day. Topics include: nutrition, fibromyalgia, e-cigarettes, cystic fibrosis, asthma, and gluten
Stool DNA (sDNA) testing, a new non-invasive technology for colon cancer screening, is a promising alternative to colonoscopy for African Americans, according to a new study presented at Digestive Disease Week.
ATS 2015, DENVER ─ Regular use of aspirin may help slow the progression of early emphysema, according to new research presented at the 2015 American Thoracic Society International Conference.
With just one exposure to electronic-cigarette (e-cigarette) vapor, participants in a study of 30 healthy subjects demonstrated a diminishment of cough reflex sensitivity. The study was presented at the 2015 American Thoracic Society International Conference.
There is little reliable evidence that electronic cigarettes are effective for long-term smoking cessation, according to a new analysis of the currently available research which was presented at the 2015 American Thoracic Society International Conference.
Certain flavorings used in electronic cigarette liquid may alter important cellular functions in lung tissue, according to new research presented at the 2015 American Thoracic Society International Conference. These changes in cell viability, cell proliferation, and calcium signaling are flavor-dependent. Coupling these results with chemicals identified in each flavor could prove useful in identifying flavors or chemical constituents that produce adverse effects in users.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right